Diagnostic Medical reports a positive net profit for the first half of 2026.

Diagnostic Medical Systems announces a 52% increase in its EBITDA for the first half of 2026, reaching a margin of 11.7%. Consolidated revenue amounted to €22.1 million, a 6% decrease compared to 2025. Despite a 9% decline in the radiology sector, bone densitometry sales increased by 6%.

Recurring operating income increased by 185%, enabling Diagnostic Medical to generate a net profit of €0.5 million, compared to a loss of €0.1 million the previous year. This performance was achieved in a challenging market environment marked by global geopolitical and economic uncertainties.

With the continued improvement in its profitability, the group plans to maintain this positive trajectory, targeting an EBITDA margin of 14% for 2027, while investing 7% of its revenues in R&D to enrich its commercial offering.